Stemgent Archives - MassDevice

Health IT Catch-22: Electronic prescriptions could mean simultaneous reward and penalty for some providers | Funding Roundup

June 14, 2011 By MassDevice staff Leave a Comment

Damned if you do, damned if you don’t. That’s the predicament many providers find themselves in with the two current CMS e-prescription initiatives.

Medicare legislation passed in the Medicare Improvements for Patients and Providers Act of 2008 authorized the Centers for Medicare and Medicaid Services to offer incentives for meeting e-prescribing requirements, but providers who meet the standards for those rewards may still be penalized if they do not meet the threshold of sending at least 10 ePrescriptions between January 1 and June 30 of 2011.

Cambridge Endo and Stemgent bring in several million in new funding rounds

May 18, 2010 By MassDevice staff Leave a Comment

Cambridge Endoscopic Devices Inc. and Stemgent Inc. each made quick gains from multi-million dollar equity offerings that opened April 30.

Cambridge Endo, an endoscopic surgical tool maker based in Framingham, Mass., sold to one individual $3 million of a $7.5 million offering, according to Securities & Exchange Commission filings. CEO Woojin Lee and directors Walter Winshall and Phil Henderson were listed as principals in the deal.

Stemgent, Miltenyi Biotec ink strategic alliance

May 4, 2010 By MassDevice staff Leave a Comment

Stemgent Inc. and Germany-based Miltenyi Biotec inked a strategic partnership deal that will see the firms co-develop and market stem cell products.

Under the terms of the agreement, Miltenyi Biotec will be responsible for the overseas marketing and sale of Stemgent’s existing stem cell reagents, antibodies and other products, with Stemgent continuing to serve its U.S. customers. Both companies will begin to jointly develop new products, which Miltenyi Biotec will then commercialize.